Mestag was founded in 2020 by leading investigators and SV Health Investors to develop new medicines for people affected by inflammatory disease and cancer.

Biotechnology

Research

Mestag Therapeutics

Susan Hill

Eilidh Goodwin

Tim Johnson

Marta Lewandowska

Patrice Love

James Legg

Robert De Jonge

Ray Jupp

The Advisory Team at Mestag Therapeutics comprises experts who provide strategic guidance and specialized knowledge to support the development of innovative medicines for inflammatory diseases and cancer. Their insights help shape research directions, regulatory strategies, and clinical development plans.

Advisory Team

Scientific Research

Board and Executives

Advisory Team

About

Team members

Other teams at Mestag Therapeutics

Scientific Research

Board and Executives